Nasreen Najmunnisa, PhD

Nasreen Najmunnisa, PhD
Assistant Professor


TEL: 352.376.1611, ext 6491
FAX: 352.273.6172




PhD Osmania University, India Physiology/Biochemistry

Research Interests:

  • Receptor EphA2/EphrinA1 signaling in thoracic malignancies (NSCLC & malignant mesothelioma)
  • Micro RNA regulation in thoracic malignancies
  • Epithelial cell injury and airway remodeling in COPD
  • Pleural mesothelial epithelial mesenchymal transition in lung fibrosis

Professional Societies:

  • American Association of Cancer Research
  • American Thoracic Society
  • American Federation for Medical Research
  • Southeast Thoracic Association

Honors and Awards:

  • 2012, 2014 & 2015: Excellence in Research Award, Department of Medicine, University of Florida
  • 2009: NIR Award (New Investigator Research Award) –Department of Health, Florida
  • 2008: Excellence in Research Award, Department of Medicine, University of Florida
  • 2003-2004: Young Investigator Award, American Lung Association

 Editorial activities (invited reviewer):

  • American Journal of Cellular and Molecular Physiology
  • American Journal of Cancer research
  • Cell Biology International
  • Inflammation Research
  • Journal of Nano-medicine
  • Molecular Medicine
  • Pharmacological Research
  • PLOS-one
  • Respirology

Grants Funded:

  • Ongoing Research Support
  • Department of Defense: Principal Investigator “Epha2 -/- NK cell therapy against Malignant Pleural Mesothelioma.” – 2015-2017
  • Completed Research 
  • Florida Department of Health: Principal Investigator-“Micro-RNA Based Novel Targeted Therapy for Malignant Pleural Mesothelioma- 2013-2015
  • Department of Medicine-Gatorade: Principal Investigator “Significance of Micro-RNA in Malignant Pleural Mesothelioma”- 2013-2015
  • Florida Department of Health: Principal Investigator-“Intratumoral Gene Therapy (ITGT) in mouse model for lung cancer”- 2010-2013
  • GlaxoSmithKline: Principal-investigator “MicroRNAs as signatures of FP/SAL mediated inhibition of inflammation and airway remodeling in mouse model of COPD” -2012-2013
  • Florida Department of Health- NIR: Principal Investigator-“Eph-A2 Signaling in Tobacco Smoke Induced Bronchial Airway Epithelial Injury”- 2009-2012
  • GlaxoSmithKline: Co-investigator “Significance of SOCS-3 in airway inflammation in COPD” -2010-2011
  • VA-Merit Review: Consultant “Mechanisms of Development of Pleural Fibrosis”-2011-2014
  • Flight Attendant Medical Research Institute: Co-Investigator “Second Hand Smoke (SHS) and airway infection-2007-2010
  • National Institutes of Health: Co-Investigator “Monocyte Recruitment in Pleuro-Pulmonary TB in AIDS” 2001-2006
  • American Association of Lung Cancer: Principal Investigator ““Mechanism of talc induced Pleurodesis” 2003-2004

Representative Publications (selected):

  • Lee HY, Mohammed KA, Goldberg EP, Kaye F, Nasreen N. Cisplatin loaded albumin mesospheres for lung cancer treatment. Am J Cancer Res. 2015 Jan 15; 5(2):603-15. eCollection 2015.
  • Nasreen N, Khodayari N, Sriram PS, Patel J, Mohammed KA. Tobacco smoke induces epithelial barrier dysfunction via receptor EphA2 signaling. Am J Physiol Cell Physiol. 2014 Jun 15; 306(12):C1154-66.
  • Lee HY, Mohammed KA, Kaye F, Sharma P, Moudgil BM, Clapp WL, Nasreen N. Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer. J Nanomedicine. 2013; 8:4481-94.
  • Nasreen N, Khodayari N, Mohammed KA. Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach. Am J Cancer Res. 2012; 2(2):222-34.
  • Sukka-Ganesh B, Mohammed KA, Kaye F, Goldberg EP, Nasreen N. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene. BMC Cancer. 2012 Jul 23; 12:309.
  • Lee HY, Mohammed KA, Peruvemba S, Goldberg EP, Nasreen N. Targeted lung cancer therapy using ephrinA1-loaded albumin microspheres. J Pharm Pharmacol. 2011 Nov; 63(11):1401-10.
  • Mohammed KA, Wang X, Goldberg EP, Antony VB, Nasreen N. Silencing receptor EphA2 induces apoptosis and attenuates tumor growth in malignant mesothelioma. Am J Cancer Res. 2011; 1(3):419-431.
  • Khodayari N, Mohammed KA, Goldberg EP, Nasreen N. EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene. Cancer Gene Ther. 2011 Nov; 18(11):806-16.
  • Nasreen N., Mohammed KA, Mubarak KK, Baz MA, Akindipe OA, Fernandez-Bussy S, Antony VB. Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-β1 in vitro. Am J Physiol: Lung Cell Mol Physiol. 2009 Jul; 297(1):L115-24.
  • Nasreen N., Mohammed K.A., Scott Brown, Su, Y., Sriram, P.S., Moudgil, B., Loddenkemper, R., and Antony, V.B.  Angiogenic balance in Malignant Pleural Effusions: Talc Mediates switch to angiostasis via Endostatin Induction in Pleural Mesothelial Cells. Resp. Journal.  2007, Apr; 29(4):761-9.
  • Nasreen N., Mohammed K.A., and Antony V.B. Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM).  Cancer Lett. 2007 Dec 18; 258(2):215-22.
  • Nasreen N., Mohammed K.A., and Antony V.B. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells.  Cancer. 2006 Nov 15; 107(10):2425

Please click here for a list of Dr. Nasreen’s industry relationships.